Drug Trial Radar · NCT03375320
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
298
Actual
Start
Oct 26, 2018
Primary completion
Aug 23, 2023
Study completion Sep 1, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Dec 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
Conditions
- Functioning Pancreatic Neuroendocrine Tumor
- Intermediate Grade Lung Neuroendocrine Neoplasm
- Locally Advanced Digestive System Neuroendocrine Neoplasm
- Locally Advanced Digestive System Neuroendocrine Tumor G1
- Locally Advanced Lung Neuroendocrine Neoplasm
- Locally Advanced Pancreatic Neuroendocrine Tumor
- Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm
- Low Grade Lung Neuroendocrine Neoplasm
- Lung Neuroendocrine Tumor
- Lung Neuroendocrine Tumor G2
- Metastatic Digestive System Neuroendocrine Neoplasm
- Metastatic Digestive System Neuroendocrine Tumor G1
- Metastatic Lung Neuroendocrine Neoplasm
- Metastatic Lung Neuroendocrine Tumor
- Metastatic Pancreatic Neuroendocrine Neoplasm
- Metastatic Pancreatic Neuroendocrine Tumor
- Metastatic Thymus Neuroendocrine Neoplasm
- Neuroendocrine Neoplasm
- Neuroendocrine Tumor
- Neuroendocrine Tumor G2
- Non-Functioning Pancreatic Neuroendocrine Tumor
- Pancreatic Serotonin-Producing Neuroendocrine Tumor
- Thymus Neuroendocrine Tumor
- Unresectable Digestive System Neuroendocrine Neoplasm
- Unresectable Digestive System Neuroendocrine Tumor G1
- Unresectable Lung Neuroendocrine Neoplasm
- Unresectable Pancreatic Neuroendocrine Neoplasm
- Unresectable Thymus Neuroendocrine Neoplasm
Interventions
Biospecimen CollectionProcedure
Undergo blood and urine sample collection
Cabozantinib S-malateDrug
Given PO
Computed TomographyProcedure
Undergo CT
Magnetic Resonance ImagingProcedure
Undergo MRI
Placebo AdministrationOther
Given PO
Quality-of-Life AssessmentOther
Ancillary studies
X-Ray ImagingProcedure
Undergo x-ray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: 36 months
Locations
432 sites in 1 country. Site status is shown where the registry gives one.
Katmai Oncology Group
Anchorage, Alaska
Kingman Regional Medical Center
Kingman, Arizona
Mayo Clinic Hospital in Arizona
Phoenix, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Mills-Peninsula Medical Center
Burlingame, California
City of Hope Comprehensive Cancer Center
Duarte, California
Epic Care-Dublin
Dublin, California
Epic Care Partners in Cancer Care
Emeryville, California
Kaiser Permanente-Fremont
Fremont, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Kaiser Permanente-Fresno
Fresno, California
Contra Costa Regional Medical Center
Martinez, California
Fremont - Rideout Cancer Center
Marysville, California
Memorial Medical Center
Modesto, California
Kaiser Permanente-Modesto
Modesto, California
Palo Alto Medical Foundation-Camino Division
Mountain View, California
Alta Bates Summit Medical Center - Summit Campus
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
Kaiser Permanente-Redwood City
Redwood City, California
Kaiser Permanente-Richmond
Richmond, California
Kaiser Permanente-Roseville
Roseville, California
Sutter Roseville Medical Center
Roseville, California
Kaiser Permanente Downtown Commons
Sacramento, California
Sutter Medical Center Sacramento
Sacramento, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Kaiser Permanente-South Sacramento
Sacramento, California
Salinas Valley Memorial
Salinas, California
California Pacific Medical Center-Pacific Campus
San Francisco, California
Kaiser Permanente-San Francisco
San Francisco, California
UCSF Medical Center-Mission Bay
San Francisco, California
Kaiser Permanente-Santa Teresa-San Jose
San Jose, California
Kaiser Permanente San Leandro
San Leandro, California
Showing 40 of 432 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.